Greenberg Traurig is a sponsor of the 2024 DeviceTalks Boston May 1-2 at the Boston Convention and Exhibition Center. DeviceTalks is an essential meeting for entrepreneurs, engineers, and other professionals developing the latest tools used to treat patients and cure disease. DeviceTalks Boston will unite Medtech’s most innovative professionals to find the quickest way to clear troublesome bottlenecks in these critical stages: innovation & funding; prototyping and product development; manufacturing & sourcing; regulatory, reimbursement and market development; and engineering tools & technology.
Greenberg Traurig Shareholders David Dykeman, co-chair of the Global Life Sciences & Medical Technology Group, and Roman Fayerberg will speak during the "How IP Can Drive Funding & Exits" session on May 1. The session will bring together medtech VCs and CEOs as they delve into strategies for positioning your medtech company to attract investors, collaborators, and acquirers. Intellectual Property (IP) is critical for medtech companies to attract funding, strategic partners, and navigate an exit through M&A or IPO. To become attractive funding or M&A targets, medtech companies must prioritize de-risking and aligning their commercial, regulatory, and IP strategies. This session will provide insights into best practices and pitfalls to avoid when building strategic patent portfolios to close funding, stay competitive, and secure a successful exit.